- As of 2/01/2017, 52 pts were treated on study (1 each at DL1 and DL3, 7 at DL2, 2 at DL4, 4 at DL5, 24 at DL-1 and 13 at DL-2)
- 20.8% of pts remain alive at 36-month post PVSRIPO infusion, compared to 4% of an historical control.
- Four pts remain alive more than 22 months post treatment without having received any additional intervention following PVSRIPO at 57.5+, 56.4+, 27.9+ and 23.2+ months.
An important thing to keep in mind is that the patients in this phase 1 trial were treated with various doses of the virus. We can expect future trials that move forward with the approximately optimal dose to have better overall results than this trial. The first patient in this trial is now 5 years in remission.